New skin lightening ingredient passes safety tests
The company’s contract research organisation (CRO) has subjected the new compound to extra tests, Sirona Biochem states, and the successful results will now allow formulators across Asia, Europe and North America to begin trailing applications of the product.
"As part of due diligence of a third party, our CRO performed additional safety and efficacy studies with our innovative skin lightening compound SBM-TFC-1067 in the last several weeks,” the company said in a statement.
“The results are a major milestone that will significantly help us to close a licensing deal for this new compound in due course.
“Furthermore, it will provide scientific credibility enabling potential partners to initiate formulation and clinical trials required for approval of SBM-TFC-1067 in the major markets of the world (Japan, Korea, China, Europe and North America)," confirmed Dr. Howard Verrico, CEO of Sirona Biochem.
Simple and cost effective
The production of the new ingredient involves a novel, efficient process of just three steps, reportedly made possible by Sirona Biochem’s fluorination technology.
The benefits of this simple and cost effective process have resulted in an ingredient that offers a higher profit margin for cosmetics companies, Sirona executives claim.
A preliminary estimation of COGs for the active ingredient yielded CAD$0.10 per 100 ml final formulation at a final concentration of 0.1%, the company’s research and development team claims.
Sirona Biochem states it is set to present the new results for its 1067 compound at various major industries shows in the weeks ahead, including the China Beauty Expo 18 - 20 May, COSM’innov 2016 in France 24 - 25 May, and Innocos World Beauty Innovation in Austria, 9 - 10 June.
The global skin lightening or whitening market is tipped to reach $39.75 billion by 2019, a lucrative sector which is prompting ever-increasing investment in R&D and formulation by beauty players.
